This study compared investigator ratings of ADHD symptoms based on interviews with parents and teachers during a doubleblind, placebo-controlled study of atomoxetine. Investigators completed the ADHD Rating Scale: Investigator (ADHDRS-I) based on separate semistructured interviews with the primary caretaker and teacher of the participant. Interviews were conducted at Visits 2 to 7 during a double-blind treatment protocol comparing atomoxetine (N= 10) and placebo (N= 6). Both parent and teacher-based ratings were sensitive to change in ADHD symptoms with atomoxetine treatment. Parent-based assessment differentiated significantly between treatment with atomoxetine and placebo, whereas teacher-based assessment was less sensitive to change. Parents and teachers showed good agreement on change in ADHDRS-I scores. Investigator ratings based on parent- and teacher-report were sensitive to change in symptoms of ADHD during treatment with atomoxetine. Despite good agreement between parent- and teacher-based ratings of symptom change, parent-based ADHD symptom ratings are more sensitive to symptom change.
Achenbach, T. M., McConaughy, S. H.,& Howell, C. T. (1987). Child/ adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin, 101, 213-232.
2.
Allen, A. J., Thomason, C., Lambrect, L., Tamura, R., Tannock, R., Weiss, M., et al. (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Manuscript not submitted for publication.
3.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders(4th ed.). Washington, DC: Author.
4.
Barkley, R. A. (1998). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment(2nd ed.). New York: Guilford.
5.
Biederman, J., Faraone, S. V., Monuteaux, M. C., & Grossbard, J. R. (2004). How informative are parent reports of attention-deficit/ hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics, 113, 1667-1671.
6.
Birmaher, B., Axelson, D. A., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., et al. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 415-423.
7.
Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
8.
Conners, C. K., & Barkley, R. A. (1985). Rating scales and checklists for child psychopharmacology. Psychopharmacology Bulletin, 21, 809-843.
9.
DuPaul, G. J., Power, T. J., Anastopoulos, A. D., & Reid, R. (1998). ADHDRating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford.
10.
Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., et al. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1205-1215.
11.
Faraone, S. V., Biederman, J.,& Roe, C. (2002). Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Clinical Psychopharmacology, 22, 468-473.
12.
Faries, D. E., Yalcin, I., Harder, D.,& Heilgenstein, J. H. (2001). Validation of the ADHD Rating Scale as a clinician administered and scored instrument. Journal of Attention Disorders, 5, 107-115.
13.
Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E., & Blumer, J. L. (2000). A double-blind study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 509-516.
14.
Goldstein, D. J., Mallinckrodt, C., Lu, Y.,& Demitrack, M. A. (2002). Duloxetine in the treatment of major depressive disorder: A doubleblind clinical trial. Journal of Clinical Psychiatry, 63, 225-231.
15.
Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., et al. (1997). Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (KSADSPL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 980-988.
16.
King, N. J., Tonge, B. J., & Mullen, P. M. (2000). Treating sexually abused children with posttraumatic stress symptoms: A randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 1347-1355.
17.
Kratochvil, C. J., Heiligenstein, J. H., Dittmann, R., Spencer, T. J., Biederman, J., Wernicke, J., et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: Aprospective, randomized, open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 776-784.
18.
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, E83-E83.
19.
The Multimodal Treatment of ADHD Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
20.
Pedhazur, E. J. (1982). Multiple regression in behavioral research (2nd ed.). New York: Holt, Rinehart & Winston.
21.
Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal, 165, 1475-1488.
